XML 36 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
8. STOCKHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
NOTE 8. STOCKHOLDERS' EQUITY

Our board of directors may, without further action by our stockholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of such preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of the Company before any payment is made to the holders of our common stock. Furthermore, the board of directors could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of our common stock.

 

Convertible Series A Preferred Stock

 

Our authorized Convertible Series A Preferred Stock, $0.01 par value consists of 1,000,000 shares. At December 31, 2016 and 2015, there were 510,000 shares issued and outstanding, respectively. The Convertible Series A Preferred Stock is convertible at the rate of one share of common stock for one share of Convertible Series A Preferred Stock.

 

Convertible Series B Preferred Stock

 

Our authorized Convertible Series B Preferred Stock, $1,000 stated value, 7.5% Cumulative dividend, consists of 4,000 shares. At December 31, 2016 and 2015, there were no shares issued and outstanding, respectively.

 

Common Stock

 

During the year ended December 31, 2015, we issued 1,094,679 shares of common stock valued at approximately $454,418 for services rendered (Note 11).   In addition, we issued 225,000 shares of common stock valued at $101,250 to Harold Paul as payment for legal services rendered (Note 9).

 

During the year ended December 31, 2015, our Board of Directors approved the issuance of 225,000 shares of common stock from the 2008 Plan valued at $101,250 as a bonus to Halden Shane, CEO, in August 2015 (Note 9).

 

During the year ended December 31, 2015, we issued 50,146 shares of common stock valued at $18,000 to Nick Jennings, CFO, as part of his annual compensation from the Company.  In addition, our Board of Directors approved the issuance to Mr. Jennings of 62,000 shares of common stock under the Company’s 2008 Plan valued at $27,900 as a bonus in August 2015 (Note 9).

 

During the year ended December 31, 2015, our Board of Directors approved the issuance of 100,000 shares of common stock from the 2008 Plan valued at $45,000 as a bonus to Norris Gearhart, COO, in August 2015 (Note 9).

 

During the year ended December 31, 2015, we sold, 1,760,002 equity units.  Each unit consisted of 1 share of common stock and 2.5 warrants.  The warrants have an exercise price of $0.29 per share and a term of seven years. We received gross proceeds of $510,213.  In connection with the sale, we incurred a cash finder’s fee in the amount of $51,000 in addition to a finder’s fee to be paid in common stock of 52,800 shares valued at $15,312.

 

During the year ended December 31, 2015, we issued 14,913,968 shares of common stock in connection with the conversion of the convertible notes and the related accrued interest amounting to $3,897,916 (Note 6).

 

During the year ended December 31, 2015, we directly sold to two investors, 17,986,111 shares of common stock.  Gross proceeds to the Company in connection with the shares sold amounted to approximately $8,225,000.

 

During the year ended December 31, 2016, we issued 761,954 shares of common stock valued at $369,654 for professional services rendered.

 

Stock Options

 

We issued 40,000 options valued at $10,798 to two directors in January 2015. The options have an exercise price of $0.27 per share. The options expire in January 2025. The options were valued using the Black-Scholes model using the following assumptions: volatility: 237%; dividend yield: 0%; zero coupon rate: 1.61%; and a life of 10 years.

 

We issued 100,000 options valued at $54,980 to four directors in February 2016. The options have an exercise price of $0.55 per share. The options expire in February 2026. The options were valued using the Black-Scholes model using the following assumptions: volatility: 224%; dividend yield: 0%; zero coupon rate: 1.47%; and a life of 10 years.

 

The following table summarizes stock options outstanding as of December 31, 2016 and 2015:

 

   December 31, 2016  December 31, 2015
   Number of Options  Weighted Average Exercise Price  Number of Options  Weighted Average Exercise Price
 Outstanding, beginning of period    100,000   $0.96    60,000   $1.42 
 Granted    100,000    0.55    40,000    0.27 
 Exercised    —      —      —      —   
 Outstanding, end of period    200,000   $0.76    100,000   $0.96 

 

Options outstanding and exercisable by price range as of December 31, 2016 were as follows:

 

Outstanding Options 

Average

Weighted

  Exercisable Options
Range  Number 

Remaining

Contractual

Life in Years

  Number 

Weighted

Average

Exercise Price

             
$2.10    40,000    3.01    40,000   $2.10 
$0.05    20,000    4.02    20,000   $0.05 
$0.27    40,000    8.02    40,000   $0.27 
$0.55    100,000    9.10    100,000   $0.55 
      200,000    7.16    200,000   $0.76 

 

Stock Warrants

 

For the year ended December 31, 2015, we recognized equity based compensation of approximately $316,000 on the warrants issued to the CEO in connection with his previous employment agreement. In addition, we recognized approximately $10,800 for director options (See Note 8-Stock Options), $1,350,000 to consultants (Note 11), and $30,000 on the vesting of warrants issued to the CFO on October 1, 2014 (Note 11).

 

During the year ended December 31, 2015, we issued 4,400,005 warrants in connection with the equity units sold to investors. See note 8 (common stock) for additional details. In addition, we issued 3,225,000 warrants to two consultants during the year ended December 31, 2015. See note 11 (contracts and agreements) for additional details.

 

For the year ended December 31, 2016, we recognized total equity based compensation of approximately $394,000 on warrants issued to the CEO in connection with his current and previous employment agreements (Note 9). For the year ended December 31, 2016, we recognized $39,000 in stock compensation expense for the warrants issued to the CEO in February 2014 that vested in February 2016. In addition, on March 31, 2016, we issued warrants to purchase up to 250,000 shares of common stock to the CEO with a term of five years that vest upon issuance and have an exercise price of $0.50 per share. We utilized the Black-Scholes method to fair value the warrants to purchase up to 250,000 shares of common stock received by the CEO totaling approximately $129,000 with the following assumptions: volatility, 162%; expected dividend yield, 0%; risk free interest rate, 1.47%; and a life of 5 years. The grant date fair value of each warrant was $0.51. On June 30, 2016, we issued warrants to purchase up to 250,000 shares of common stock to the CEO with a term of five years that vest upon issuance and have an exercise price of $0.42 per share. The Company utilized the Black-Scholes method to fair value the warrants to purchase up to 250,000 shares of common stock received by the CEO totaling approximately $99,000 with the following assumptions: volatility, 157%; expected dividend yield, 0%; risk free interest rate, 1.17%; and a life of 5 years. The grant date fair value of each warrant was $0.40. On September 30, 2016, the Company issued warrants to purchase up to 250,000 shares of common stock to the CEO with a term of five years that vest upon issuance and have an exercise price of $0.32 per share. We utilized the Black-Scholes method to fair value the warrants to purchase up to 250,000 shares of common stock received by the CEO totaling approximately $66,000 with the following assumptions: volatility, 155%; expected dividend yield, 0%; risk free interest rate, 1.27%; and a life of 5 years. The grant date fair value of each warrant was $0.27. On December 31, 2016, we issued warrants to purchase up to 250,000 shares of common stock to the CEO with a term of five years that vest upon issuance and have an exercise price of $0.27 per share. We utilized the Black-Scholes method to fair value the warrants to purchase up to 250,000 shares of common stock received by the CEO totaling approximately $61,000 with the following assumptions: volatility, 146%; expected dividend yield, 0%; risk free interest rate, 1.95%; and a life of 5 years. The grant date fair value of each warrant was $0.24. (See note 11 for additional details).

 

For the year ended December 31, 2016, we recognized total equity based compensation of approximately $73,000 on warrants issued to the CFO in connection with his current and previous employment agreements (Note 11). For the year ended December 31, 2016, we recognized $22,000 in stock compensation expense for the warrants issued to the CFO under his previous agreement with the Company. In addition, on January 26, 2016, we issued warrants to purchase up to 100,000 shares of common stock to the CFO with a term of five years that vest upon issuance and have an exercise price of $0.55 per share. We utilized the Black-Scholes method to fair value the warrants to purchase up to 100,000 shares of common stock received by the CFO totaling approximately $51,000 with the following assumptions: volatility, 164%; expected dividend yield, 0%; risk free interest rate, 1.47%; and a life of 5 years. The grant date fair value of each warrant was $0.51. (See note 11 for additional details)

 

For the year ended December 31, 2016, we recognized equity compensation expense of approximately $92,000 related to the vested and accrual of unvested warrants contracted to an employee pursuant to his employment agreement with the Company that were issued in April 2016. We utilized the Black-Scholes method to fair value the 300,000 warrants received by the employee totaling approximately $139,000 with the following assumptions: volatility, 159%; expected dividend yield, 0%; risk free interest rate, 1.47%; and a life of 5 years. The grant date fair value of each warrant was $0.46.

 

The following table summarizes the outstanding common stock warrants as of December 31, 2016 and December 31, 2015:

 

   December 31, 2016  December 31, 2015
   Number of Warrants  Weighted Average Exercise Price  Number of Warrants  Weighted Average Exercise Price
 Outstanding, beginning of period    35,676,413   $0.30    28,051,408   $0.23 
 Granted    1,400,000    0.42    7,625,005    0.58 
 Expired    (375,000)   0.05    —      —   
 Outstanding, end of period    36,701,413   $0.31    35,676,413   $0.30 

 

Warrants outstanding and exercisable by price range as of December 31, 2016 were as follows: 

 

 Outstanding Warrants    Exercisable Warrants
 Range    Number    

Average

Weighted

Remaining

Contractual

Life in Years

    Number    

Weighted

Average

Exercise Price

 
$0.01    1,575,000    0.53    1,575,000   $0.01 
$0.05    600,000    1.00    600,000   $0.05 
$0.15    7,750,000    0.80    7,750,000   $0.15 
$0.26    100,000    1.49    100,000   $0.26 
$0.27    250,000    5.00    250,000   $0.27 
$0.29    10,125,613    3.81    10,125,613   $0.29 
$0.30    11,925,800    1.75    11,925,800   $0.30 
$0.32    250,000    4.75    250,000   $0.32 
$0.33    75,000    1.75    75,000   $0.33 
$0.42    250,000    4.50    250,000   $0.42 
$0.50    625,000    3.93    425,000   $0.50 
$0.55    100,000    4.08    100,000   $0.55 
$0.62    75,000    1.55    75,000   $0.62 
$1.00    3,000,000    3.34    3,000,000   $1.00 
      36,701,413    2.26    36,501,413   $0.31 

 

Unvested warrants outstanding as of December 31, 2016 were as follows:

 

  Unvested Warrants 
 

Weighted

Average

Exercise Price

    Number    

Average

Weighted

Remaining

Contractual

Life in Years

 
$0.50    200,000    5.00